[HTML][HTML] TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
Journal of clinical oncology, 2011•ncbi.nlm.nih.gov
Purpose To determine the frequency of TET2 mutations, their associations with clinical and
molecular characteristics and outcome, and the associated gene-and microRNA-expression
signatures in patients with primary cytogenetically normal acute myeloid leukemia (CN-
AML).
molecular characteristics and outcome, and the associated gene-and microRNA-expression
signatures in patients with primary cytogenetically normal acute myeloid leukemia (CN-
AML).
Abstract
Purpose
To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene-and microRNA-expression signatures in patients with primary cytogenetically normal acute myeloid leukemia (CN-AML).
ncbi.nlm.nih.gov